Massachusetts Department of Public Health (MDPH)

Immunization Program

**Childhood Vaccine Availability Table**

**– Effective November 2023 –**

**Eligibility Categories:**

* **All Children:** Vaccine provided by MDPH for identified cohorts, regardless of insurance status.
* **Vaccines for Children (VFC) Program Only:** Vaccine provided by MDPH for identified cohorts who are: 1) uninsured; 2) enrolled in MassHealth/Medicaid; 3) American Indian or Alaska Native; or 4) underinsured (insurance does not cover the vaccine) andseen at a federally qualified community health center. Children who are enrolled in secondary MassHealth insurance should also be screened as VFC Eligible. Children enrolled in sCHIP, or the Children’s Medical Security Plan (CMSP) may receive all vaccines on the Childhood Availability Table but are not considered VFC eligible when screening or assessing for VFC eligibility.

(Please note vaccines available only for VFC eligible groups appear shaded)

|  |  |  |
| --- | --- | --- |
| **Vaccine** | **Eligibility** | **DPH-Supplied Vaccine Available For:** |
| **COVID-19** | **All** | * All children aged 6 months – 18 years
 |
| **DTaP** | **All** | * All children aged 2 months – 6 years
 |
| **DTaP-Hep B-IPV**  | **All** | * All children aged 2 months – 6 years for the first 3 doses of DTaP and IPV and any dose of Hep B at 2, 4 and 6 months
* Not approved for dose 4 or 5 of the DTaP series or dose 4 of the IPV series
 |
| **DTaP-IPV-Hib** | **All** | * All children aged 2 months – 4 years for the first 4 doses of DTaP, IPV and Hib at 2, 4, 6 and 15 – 18 months
 |
| **DTaP-IPV** | **All** | * All children aged 4 – 6 years for routine immunization for the 5th dose of the DTaP series and 4th dose of the IPV series
* Not approved for the first 3 doses of DTaP and IPV or dose 4 of the DTaP series
 |
| **DTaP-IPV-Hib-Hep B**  | **All** | * All children aged 6 weeks through 4 years for the first 3 doses of DTaP, Polio and Hib at 2, 4 and 6 months.
* Not approved for the hepatitis B birth dose.
* Not approved for dose 4 or 5 of DTaP or dose 4 of IPV or dose 4 of Hib.
 |
| **Hep A** | **All** | * Routine vaccination of the 1st and 2nd dose for children aged 12 – 23 months
* Catch-up vaccination of children aged 2 – 18 years
* Infants 6-11 months, one dose before international travel; revaccinate with 2-dose series at 12-23 months.
 |
| **Hep B** | **All** | * All children through 18 years of age
 |
| **Hib** | **All** | * All children aged 2 – 59 months
* Children aged > 5 years in an ACIP-recommended group\*
 |
| **HPV** | **All** | * All children 9 – 18 years of age
 |
| **Influenza** | **All** | * All children aged 6 months through 18 years
 |

|  |  |  |
| --- | --- | --- |
| **Vaccine** | **Eligibility** | **DPH Supplied Vaccine Available For:** |
| **MCV4-ACWY** | **All** | * All adolescents 11 – 18 years of age

Note: first dose routinely recommended at 7th grade entry, 11 – 12 years of age, and second dose at 16 – 18 years of age * High risk\* children 2 months - 18 years, all doses, including boosters. Schedule depends on age and formulation. High risk includes: functional or anatomic asplenia (sickle cell), complement deficiencies, travelers, occupational risk, outbreaks.

Note:* Menveo (one-vial formulation) approved beginning at 10 years
* MenQuadfi approved beginning at 2 years
* Menveo (two-vial) approved beginning at 2 months – *this formulation should be prioritized for 2 month to 2 year olds as it is the only formulation approved for this age group*
 |
| **MenB**  | **All** | During a serogroup B meningococcal disease outbreak the followinghigh risk children 10 – 18 years of age in the following risk groups are eligible: * Persistent complement component deficiencies (including: inherited or chronic deficiencies in C3, C5-9, properdin, factor D, factor H, or taking eculizumab [Soliris®]).
* Anatomic or functional asplenia (including: sickle cell).
* Microbiologists routinely exposed to isolates of Neisseria meningitidis.
 |
| **VFC Only** | * May be considered for healthy adolescents 16 – 18 years of age to provide short term protection against most strains of serogroup B meningococcal disease (permissive recommendation).
 |
| **MMR** | **All** | * All children aged 12 months – 18 years
* Infants 6 – 11 months, 1 dose before any international travel; revaccinate with 2-dose series at age 12-15 months
 |
| **MMRV**  | **All** | * All children aged 12 months – 12 years who require both MMR and varicella vaccines

Note: ACIP recommends the 1st dose in the series for children 12 – 47 months be given as separate injections of MMR and varicella vaccines and generally recommends MMRV for the 2nd dose in the series or for the 1st dose for those > 48 months. See [ACIP](http://www.cdc.gov/mmwr/pdf/rr/rr5903.pdf) statement for full guidance.  |
| **Mpox** | **All** | * High risk\* children aged 18 years
 |
| **PCV20**(Pneumococcal Conjugate) | **All** | * All children aged 2 – 59 months
* High risk\* children through age 18 years

Note: See ACIP statement for full guidance.  |
| **PPSV23**(Pneumococcal Polysaccharide) | **All** | * Children 2 through 18 years old with certain risk\* conditions who receive/received PCV13 or PCV15 only
 |
| **Polio** | **All** | * All children aged 2 months – 18 years
 |
| **Rotavirus** | **All** | * All infants aged 6 weeks – 8 months 0 days
 |
| **RSV (nirsevimab)** | **All** | * All infants aged <8 months born during or entering their first RSV season ( (50 mg for infants weighing <5 kg/<11 lb and 100 mg for infants weighing ≥5 kg/≥11 lb)
* Infants and children aged 8–19 months who are at increased risk\* for severe RSV disease and entering their second RSV season ( (200 mg, administered as two 100 mg injections given at the same time at different injection sites)

Note: See [ACIP](https://www.cdc.gov/mmwr/volumes/72/wr/mm7234a4.htm) statement for full guidance. See the Oct 2023 CDC [HAN Advisory](https://emergency.cdc.gov/han/2023/han00499.asp) for interim clinical guidance in the context of the 2023/2024 nirsevimab supply shortages |
| **Td** | **All** | * All children aged 7 – 18 years
 |
| **Tdap** | **All** | * All children aged 7 – 18 years Note: routinely recommended at 7th grade entry, 11 – 12 years of age
 |
| **Varicella** | **All** | * All children aged 12 months – 18 years
 |

\*High risk children as defined by the ACIP, including those exposed in an outbreak setting who are not fully vaccinated.

For a list of vaccines and the groups for whom vaccine is recommended, please see the MDPH *Summary of* *Advisory Committee on Immunization Practices (ACIP) Recommended Groups for Vaccination.* For the complete ACIP recommendations, see <http://www.cdc.gov/vaccines/acip/index.html>.